What is TRIOMICS?
TRIOMICS operates at the intersection of healthtech and enterprise software, providing a sophisticated platform designed to harness the maturity of US healthcare data systems. By addressing the inherent limitations of current clinical research frameworks, the company empowers healthcare organizations to navigate the complexities of FHIR adoption. Its technology serves as a critical bridge for institutions seeking to optimize data utility, ensuring that clinical research is both scalable and compliant with modern digital health standards. As the industry shifts toward more integrated data ecosystems, TRIOMICS occupies a pivotal position in enabling seamless information exchange for research-driven healthcare entities.
How much funding has TRIOMICS raised?
TRIOMICS has raised a total of $37M across 2 funding rounds:
Series A
$15M
Series B
$22M
Series A (2024): $15M with participation from Y Combinator, General Catalyst, Lightspeed, and Nexus Venture Partners
Series B (2026): $22M led by Battery Ventures, Nexus Venture Partners, Lightspeed Venture Partners, and Y Combinator
Key Investors in TRIOMICS
Battery Ventures
A global investment firm that partners with entrepreneurs to build and scale category-defining technology businesses through strategic guidance and industry expertise.
General Catalyst
A venture capital firm focused on supporting transformational business opportunities across multiple sectors, including healthcare and enterprise software, at critical inflection points.
Lightspeed Venture Partners
A global multistage venture capital firm that invests in early and growth-stage technology companies, providing support from seed through IPO.
What's next for TRIOMICS?
With the recent influx of capital, TRIOMICS is poised to accelerate its product development roadmap and expand its footprint within the clinical research sector. The strategic focus will likely center on deepening its FHIR-native capabilities and enhancing its suite of next-generation applications for healthcare providers. By utilizing this investment to strengthen its market position, the company is set to address the growing demand for interoperable data solutions that facilitate faster, more accurate clinical insights. Future growth will be defined by the firm's ability to translate its technological advantage into widespread enterprise adoption, solidifying its role as an essential infrastructure provider in the evolving digital health landscape.
See full TRIOMICS company page
